The National Health Service is using new technology to measure the age of its patients and staff, with the aim of saving millions of pounds in health costs.
The technology is being used to test how well the NHS’s ageing population is protected against cancer and other diseases, and how well it is managing people with dementia and other health problems.
The test is being carried out by the NHS England clinical commissioning group (CCG) in partnership with the UK’s leading imaging firm, Imager, and the medical research company Cambridge Analytica.
The first tests are due to be carried out in December and will test how many people are older than the NHS average, as well as how well they respond to a range of drugs and treatments.
Imager has previously used a similar technique to determine the age and body mass index (BMI) of people with breast cancer.
Imaging is being performed by Cambridge Analyts, a company owned by Donald Trump’s political opponents, which has developed software that can read blood, saliva and other bodily fluids to detect the genetic changes associated with ageing.
It can then calculate a patient’s age using that data, which can be used to make a patient more or less fit for work, according to a statement from Imager.
It’s the latest effort to analyse how well patients are surviving in the NHS.
Last month, the Government announced it would spend £1.6bn over five years on new drugs to treat the spread of the pandemic.
The NHS is the only UK health service that has not yet deployed any of these drugs.
The Government also announced a £100m fund to support companies that develop new treatments for the pandemics, which will be available to all NHS patients, regardless of their age.NHS bosses say the new technology could be particularly helpful in older people, who have higher risk factors for diseases such as heart disease, stroke and dementia, and who may be at increased risk of infections.
In a statement, the CCG said the new technologies would help to identify those patients who are likely to need more intensive treatment.
Imagers results are based on its “gold standard” technology, which uses a mixture of digital blood, body fluids and saliva to analyse the individual’s blood cells.
The technology was introduced in 2005, when it was used in the US to detect lung cancer.
It uses sophisticated statistical techniques to determine a patient is at increased or decreased risk of dying.
Images the blood cells of older people by detecting how they change with age, and then using computer algorithms to analyse which cells are more likely to die or be damaged.
Imaged patients can then be compared to people in the general population to find out how they respond when a treatment is applied to them.
Imager’s technology is the first to be tested in the UK, and has been used in previous tests in other countries.
“The most important thing is to make sure the patient has a safe and effective treatment,” said Dr Michael Wilson, Imagers director of research.
“A number of the things that are being tested now are very different from what was used back in 2005.”
Dr Wilson said Imager would use the new tests to identify which patients could be at greater risk of disease.
“We will look at how well we can monitor the patient and how quickly they respond,” he said.
“This is a very powerful way of doing that.”‘
The NHS is on the frontline’Imager is testing the accuracy of the new tools as it looks to expand its scope beyond older people to the whole of the population.
“Imager’s ability to see the human body is the ability to monitor the health of a patient and their body in real time,” said Prof Nick Cairns, the director of medical research at Cambridge Analysts.
“With our technology, we can look at a person’s whole body and see how many times they move their arms, their legs, their torso, the way they walk, their balance.
We can see how much weight they’re carrying.
We can also see the way their blood vessels are and see if they have any problems, which is important for understanding diseases and other conditions.”
Dr Cairnas said Imagers technology could help to better understand the mechanisms that underlie the ageing process.
“It’s very much like being in the trenches,” he told ABC Radio Adelaide.
“There’s a whole range of techniques that have been used, from blood tests to ultrasound, to see how well you’re doing in terms of your physical performance, and you can see that through these new tests.”
“We can’t predict what the outcome will be, but the best way to protect the NHS is to protect patients.”
If the technology can help to make more effective treatments, then it can also help to save the NHS money.
“In the meantime, the NHS has a very strong frontline in every aspect of our healthcare system.”
Dr John Walker,